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Cox regression analysis of 30 untreated patients revealed
that only a high-grade DN was significantly associated with
an increased risk of the progression to HCC (P<0.05), as
was neither arterial phase enhancement nor size of nodule.
Additional immunohistochemical staining of 26 untreated RN
or DN specimens identified no significant histologic predictor
for HCC development. Conclusion: Our findings suggest that
more careful and active surveillance for HCC is needed in
cirrhotic patients with high-grade DNs in the liver, for which
LAT could be considered likely with a preemptive intent. Future
studies should focus on the development of biopredictives for
malignant transformation of hepatic nodules.
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metastasis [18.1% vs. 8.2%; (p<0.01)], and were less likely
to be within Milan criteria [31.6% vs. 49.7%; (p<0.01)] than
patients with NASH cirrhosis. Over the past 15-year period, we
found a trend of increasing proportion of patients who would
have been classified as cryptogenic cirrhosis being diagnosed
with NASH cirrhosis (0% in 2000, 16.7% in 2005, 27% in
2010, and 56.3% in 2015). Conclusion: The prevalence of
hypertension, diabetes mellitus, and dyslipidemia in NASH
cirrhosis and CC patients with HCC were similar. CC patients
were more likely to have more advanced HCC at diagnosis.
Finally, there is an increasing trend in NASH cirrhosis and a
decreasing trend in cryptogenic cirrhosis in patients with no
identifiable cause of liver disease.
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HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC
STEATOHEPATITIS AND CRYPTOGENIC CIRRHOSIS OVER A
15-YEAR PERIOD
Kanokwan Pinyopornpanish1, Wael Al-Yaman2, Miguel
Salazar2, Gianina Flocco3, Ji Seok Park4 and Arthur J.
McCullough3, (1)Medicine, Chiang Mai University, (2)
Gastroenterology, Hepatology & Nutrition, Cleveland Clinic
Foundation, Digestive Disease Institute, (3)Cleveland Clinic
Foundation, (4)Cleveland Clinic Foundation, Digestive
Disease Institute
Background: Non-alcoholic steatohepatitis (NASH) has
been recognized as the main cause of cirrhosis in patients
previously categorized under the term “cryptogenic cirrhosis”
(CC). The data regarding similarities and disparities between
hepatocellular carcinoma (HCC) patients with either NASH
cirrhosis or CC remains limited. We aimed to study the
characteristics and trend of biopsy-proven NASH cirrhosis
and CC in patients with HCC. Methods: We identified all
adult patients with HCC and concomitant diagnosis of NASHrelated cirrhosis or cryptogenic cirrhosis who received care at
two quaternary liver transplant centers in the United States,
between January 2000 and December 2015. Presence
of liver cirrhosis was determined based on radiologic and
histologic evidence. CC was determined in patients who
had no identifiable cause of cirrhosis after extensive clinical,
serological and pathological evaluations. Patient with excessive
alcohol consumption were excluded. HCC was diagnosed by
either pathological diagnosis or radiological diagnosis of Liver
Imaging Reporting and Data System (LI-RADS) 5 criteria.
Descriptive statistics were presented by mean and standard
deviation or median and percentiles for continuous variables
and frequencies for categorical variables. Statistical difference
between the groups were analyzed using the chi-square
test, fisher exact test, student t-test or Mann-Whiney U- test
as appropriate. Results: A total of 328 HCC patients were
included in the study, 195 patients with biopsy-proven NASH
cirrhosis and 133 patients with CC, of which 35 patients had
liver biopsy and 98 patients without liver biopsy. Patients with
CC were older [(69.9 ± 10.2 vs. 66.9 ± 8.4 years; (p=0.004)].
The prevalence of metabolic risk factors, hypertension (71%
vs. 69%), diabetes mellitus (67% vs. 59%), and dyslipidemia
(47% vs. 41%) in patients with NASH cirrhosis and CC were
similar (all P=NS), however, obesity was more prevalent in
NASH cirrhosis patients than in CC patients [63% vs. 44%
(p=0.001)]. Those with CC had higher median tumor size [5.9
(IQR 3.1, 9.3) vs. 3.5 (IQR 2.6, 5) cm], more extrahepatic
s Denotes AASLD Presidential Poster of Distinction
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HEREDITARY HEMOCHROMATOSIS AS AN INDEPENDENT RISK
FACTOR FOR LIVER CANCER: A MATCHED CASE-CONTROL
STUDY OF THE NATIONAL INPATIENT SAMPLE DATABASE
Maryam Haider1, Ali F Alsbihi1, Zaid Imam2, Adnan Malik3,
Sana Iqbal1, Mahum Nadeem4 and Ahmed J Chaudhary1,
(1)Internal Medicine, Detroit Medical Center / Wayne State
University, Sinai Grace Hospital, (2)Gastroenterology, William
Beaumont Hospital, Royal Oak, (3)Internal Medicine, Loyola
University Health System, (4)Internal Medicine, University of
Oklahoma
Background: Hereditary hemochromatosis (HH) is a genetic
metabolic disorder that increases alimentary iron absorption
resulting in the iron overload that can be carcinogenic. In
this study, we investigated the carcinogenic potential of
HH resulting in liver cancer not only through development
of cirrhosis but also in relation to hepatic iron deposition.
a Denotes AASLD Foundation Abstract Award Recipient
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Methods: We conducted a retrospective matched casecontrol analysis study from National Inpatient Sample
(NIS) database between 2016 and 2018. International
Classification of Diseases, Tenth Revision (ICD-10) was used
to identify patients with a primary or secondary diagnosis
of liver cancer (ICD-10 codes C22.0, C22.2, C22.3, C22.4,
C22.7, and C22.8). We selected a matched group of patients
without liver cancer with the 1:1 fixed ratio nearest neighbor
(greedy) propensity score method using the patient’s age,
sex, and race. Patients with liver cancer were established as
cases, and patients without liver cancer were established as
the control group. We also identified established risk factors
of liver cancer using ICD-10 codes, including cirrhosis, viral
hepatitis, HH (excluding cirrhosis), type 2 diabetes, alcohol,
obesity, Tobacco, Non-alcoholic fatty liver disease (NAFLD),
and transfusion of blood and blood products. Univariate and
multivariate regression analyses were conducted to identify
significant correlates of liver cancer. Statistically analysis is
performed in RStudio 1.4. P-values < 0.05 demonstrated
statistical significance. Results: 34582 patients with liver
cancer were identified. Multivariate analyses demonstrated
that cirrhosis (aOR, 46.666; 95% CI, 42.659 – 51.050), viral
hepatitis (aOR, 13.601; 95% CI, 12.603 – 14.679), hereditary
hemochromatosis excluding cirrhosis (aOR, 18.216; 95% CI,
5.348 – 62.045), type 2 diabetes (aOR, 1.613; 95% CI, 1.541
– 1.689), tobacco use (aOR, 1.131; 95% CI, 1.082 – 1.182),
NAFLD (aOR, 5.544; 95% CI, 4.709 – 6.528), blood transfusion
(aOR, 2.532; 95% CI, 2.334 – 2.746), are independent risk
factor of liver cancer. Conclusion: Patients with HH can be
at an increased risk for liver cancer independent of cirrhosis
status. This may be related to carcinogenic properties of
iron deposition related to the disease. More studies are
required in controlled settings to further consolidate these
findings.
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IMbrave150: EXPLORATORY EFFICACY AND SAFETY
OF ATEZOLIZUMAB (ATEZO) + BEVACIZUMAB (BEV) VS
SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR
CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL
PHASE III STUDY
Andrew X Zhu1,2, Richard Finn3, Michel Ducreux4, Youyou Hu5,
Nicolas Sommer6, Wendy Verret6, Laura M Kulik7 and Peter
R. Galle8, (1)Massachusetts General Hospital Cancer Center,
(2)Jiahui International Cancer Center, (3)Geffen School of
Medicine at UCLA, (4)Gustave Roussy Cancer Center, (5)F.
Hoffmann-La Roche Ltd., (6)Genentech Inc., (7)Northwestern
Memorial Hospital, (8)University Medical Center Mainz
Background: Atezo + bev has been approved in >70
countries to treat systemic treatment–naive unresectable
HCC, based on results from the IMbrave150 study
(NCT03434379; Finn RS NEJM 2020). Here, we report data
from an exploratory analysis of patients with non-viral HCC
etiology using updated IMbrave150 data (median follow-up:
15.6 mo; Finn RS ASCO GI 2021). Methods: IMbrave150
enrolled patients with systemic treatment–naive unresectable
HCC and ≥1 measurable untreated lesion (RECIST 1.1),
Child-Pugh class A liver function and Eastern Cooperative
Oncology Group performance score 0 or 1, including those
with non-viral etiology. Patients were randomized 2:1 to atezo
1200 mg + bev 15 mg/kg IV every 3 weeks or sor 400 mg
PO twice daily until unacceptable toxicity or loss of clinical
benefit per investigator. Results: Of the 501 enrolled patients,
153 (31%) had non-viral etiology (100 received atezo + bev
and 53 received sor). Patients with non-viral etiology had
baseline characteristics that were consistent with those of the
intention-to-treat (ITT) population. In the non-viral population,
median body mass index was 26.7 kg/m2 and 27.8 kg/m2 in
the atezo + bev arm and the sor arm, respectively, and alphafetoprotein ≥400 ng/mL was observed in 29 (29%) and 20
patients (38%), respectively. Among patients with non-viral
HCC, 35 (35%), 38 (38%), and 27 patients (27%) in the atezo
+ bev arm and 23 (43%), 16 (30%), and 14 patients (26%)
in the sor arm had a documented history of alcohol use, no
alcohol use, and unknown alcohol use status, respectively.
In the non-viral population, while overall survival (OS) was
similar between the atezo + bev and sor arms, progressionfree survival (PFS) and overall response rate (ORR) per IRFassessed RECIST 1.1 were improved with atezo + bev vs sor
(Table). Grade 3/4 and Grade 5 treatment-related adverse
events occurred in 34 (35%) and 4 patients (4%) in the atezo
+ bev arm (n=98) and 23 (44%) and 0 patients in the sor
arm (n=52), respectively. Conclusion: The relative benefit
of atezo + bev vs sor was maintained for PFS and ORR in
patients with non-viral etiology. Although OS in the non-viral
population was similar in both arms due to an unusually high
median OS with sor, OS in patients receiving atezo + bev was
similar in the non-viral and ITT populations. Overall, atezo +
bev showed meaningful efficacy and a tolerable safety profile
in patients with non-viral etiology, supporting the use of atezo
+ bev in this patient population.
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